Paxlovid™ reduces the incidence of pneumonia, hospitalization, and death in a cohort of COVID-19 patients from northeast Mexico

• Published in: Journal of infection and public health 2024-07, Vol.17 (7), p.102444, Article 102444
• Main Authors: Camacho Moll, María Elena, Martínez, Ana Maria Salinas, Wu, Minna, Floriano, Gloria Navarrete, Salazar, Juan Carlos Romo, Luna, Jorge Eleazar Cruz, de León, Mario Bermúdez
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; COVID-19; COVID-19 - epidemiology; COVID-19 - mortality; COVID-19 - prevention & control; COVID-19 Drug Treatment; Death; Drug combination; Female; Hospitalization; Hospitalization - statistics & numerical data; Humans; Incidence; Male; Mexico - epidemiology; Middle Aged; Nirmatrelvir and ritonavir; Pneumonia - epidemiology; Pneumonia - mortality; Pneumonia - prevention & control; Retrospective Studies; SARS-CoV-2
• ISSN: 1876-0341; 1876-035X; 1876-035X
• DOI: 10.1016/j.jiph.2024.05.001

Information on Paxlovid™ effectiveness must be monitored and updated in real world scenarios. Our research question was what is the effectiveness of Paxlovid™ in adult patients with COVID-19? Therefore, we investigated the effectiveness of Paxlovid™ on reducing the incidence of pneumonia, hospitalization, and mortality in a cohort of COVID-19 positive adult patients from northeast Mexico. A retrospective cohort study of COVID-19 positive adult patients from Nuevo Leon, Mexico from December 2020 to May 2023 (after Omicron BA-5 circulation) was performed. Paxlovid™ use was authorized in September 2022. Therefore, we analyzed effectiveness in patients with confirmed diagnosis who met selection criteria between September 2022 and May 2023 (n = 20,799; 5,673 with and 15,126 without Paxlovid™). The pneumonia (0.1% vs. 0.4%, p